BRCA1/2 testing was made commercially available in 1996 by Myriad Laboratories, Inc. Utilization of BRCA testing increased during the study period, with more patients with PSR ovarian cancer being BRCA tested after 2006, which is substantiated by outside reports of increased utilization of BRCA testing [14]. This evidence concerns the gene BRCA1 and ovarian carcinoma.